CD8A and neoplasm: Additionally, the neoantigen-specific T cells from the infiltrated CD8+ T cells in tumor tissues collected from the combined therapy group were significantly higher than that in the other treated groups (ePAC+αTIM-3 9.06±1.258% vs ePAC 4.50±0.7195% vs αTIM-3 0.89±0.0746%).